MX339014B - Modulacion de presion intersticial y suministro y distribucion viral oncolitica. - Google Patents

Modulacion de presion intersticial y suministro y distribucion viral oncolitica.

Info

Publication number
MX339014B
MX339014B MX2010012858A MX2010012858A MX339014B MX 339014 B MX339014 B MX 339014B MX 2010012858 A MX2010012858 A MX 2010012858A MX 2010012858 A MX2010012858 A MX 2010012858A MX 339014 B MX339014 B MX 339014B
Authority
MX
Mexico
Prior art keywords
distribution
viral delivery
modulating
interstitial pressure
oncolytic viral
Prior art date
Application number
MX2010012858A
Other languages
English (en)
Other versions
MX2010012858A (es
Inventor
Matthew C Coffey
Bradley G Thompson
Hardev Pandha
Original Assignee
Oncolytics Biotech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Oncolytics Biotech Inc filed Critical Oncolytics Biotech Inc
Publication of MX2010012858A publication Critical patent/MX2010012858A/es
Publication of MX339014B publication Critical patent/MX339014B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/555—Heterocyclic compounds containing heavy metals, e.g. hemin, hematin, melarsoprol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/76—Viruses; Subviral particles; Bacteriophages
    • A61K35/765—Reovirus; Rotavirus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/2013—IL-2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2720/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsRNA viruses
    • C12N2720/00011—Details
    • C12N2720/12011—Reoviridae
    • C12N2720/12032—Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

En la presente se proporcionan métodos para tratar un trastorno proliferativo en un sujeto, que comprenden reducir la presión intersticial y/o incrementar la premeabilidad vascular en el sujeto y administrar al sujeto un virus oncolítico. Los métodos mejoran el suministro y distribución viral oncolítica.
MX2010012858A 2008-05-27 2009-05-27 Modulacion de presion intersticial y suministro y distribucion viral oncolitica. MX339014B (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US5627608P 2008-05-27 2008-05-27
US11384508P 2008-11-12 2008-11-12
PCT/CA2009/000720 WO2009143610A1 (en) 2008-05-27 2009-05-27 Modulating interstitial pressure and oncolytic viral delivery and distribution

Publications (2)

Publication Number Publication Date
MX2010012858A MX2010012858A (es) 2010-12-20
MX339014B true MX339014B (es) 2016-05-09

Family

ID=41376508

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2010012858A MX339014B (es) 2008-05-27 2009-05-27 Modulacion de presion intersticial y suministro y distribucion viral oncolitica.

Country Status (11)

Country Link
US (1) US20110086005A1 (es)
EP (1) EP2296678A4 (es)
JP (2) JP2011520993A (es)
CN (1) CN102695520A (es)
AU (1) AU2009253682B2 (es)
CA (1) CA2723580A1 (es)
IL (1) IL208381A (es)
MX (1) MX339014B (es)
TW (1) TW200951143A (es)
WO (1) WO2009143610A1 (es)
ZA (1) ZA201008018B (es)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6797680B2 (ja) 2013-06-14 2020-12-16 サイオクサス セラピューティクス リミテッド Ｂ型アデノウイルスのための投与計画および製剤
SI3021859T1 (en) 2013-10-25 2018-04-30 Psioxus Therapeutics Limited Oncolytic adenoviruses equipped with heterologous genes
ES2796950T3 (es) * 2013-11-15 2020-11-30 Oncolytics Biotech Inc Virus oncolíticos y regímenes reforzados para tratamiento de cáncer
US11000559B2 (en) 2015-04-30 2021-05-11 Psioxus Therapeutics Limited Oncolytic adenovirus encoding a B7 protein
CN108697745A (zh) 2015-12-17 2018-10-23 皮斯奥克斯治疗公司 编码抗tcr复合体抗体或片段的b组腺病毒
IL303187A (en) 2016-08-29 2023-07-01 Akamis Bio Ltd Adenovirus with bispecific T cell activator
GB201713765D0 (en) 2017-08-28 2017-10-11 Psioxus Therapeutics Ltd Modified adenovirus
CA3205343A1 (en) * 2021-01-15 2022-07-21 Robert S. Schwartz Methods and devices for assessing and modifying physiologic status via the interstitial space

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4554101A (en) * 1981-01-09 1985-11-19 New York Blood Center, Inc. Identification and preparation of epitopes on antigens and allergens on the basis of hydrophilicity
US5023252A (en) * 1985-12-04 1991-06-11 Conrex Pharmaceutical Corporation Transdermal and trans-membrane delivery of drugs
US5484399A (en) * 1992-02-27 1996-01-16 Sloan-Kettering Institute For Cancer Research Process and device to reduce interstitial fluid pressure in tissue
SE9702086D0 (sv) * 1997-06-02 1997-06-02 Biophausia Ab Anti-cancer drug delivery to solid tumors
US6565831B1 (en) * 1999-02-24 2003-05-20 Oncolytics Biotech Inc. Methods for preventing reovirus recognition for the treatment of cellular proliferative disorders
US6110461A (en) * 1997-08-13 2000-08-29 Oncolytics Biotech Inc. Reovirus for the treatment of neoplasia
US6136307A (en) * 1997-08-13 2000-10-24 Oncolytics Biotech Inc. Reovirus for the treatment of cellular proliferative disorders
US6376471B1 (en) * 1997-10-10 2002-04-23 Johns Hopkins University Gene delivery compositions and methods
EP1955703A1 (en) * 1999-11-12 2008-08-13 Oncolytics Biotech Inc. Viruses for the treatment of cellular proliferative disorders
US6547777B2 (en) * 2000-02-17 2003-04-15 Sloan-Kettering Institute For Cancer Research Apparatus and method for reducing interstitial fluid pressure and enhancing delivery of a therapeutic agent
US7306902B2 (en) * 2002-06-28 2007-12-11 Oncolyties Biotech Inc. Oncolytic viruses as phenotyping agents for neoplasms
TWI289158B (en) * 2000-08-10 2007-11-01 Oncolytics Biotech Inc Method of producing infectious reovirus
AR035227A1 (es) * 2001-02-20 2004-05-05 Oncolytics Biotech Inc Uso de un agente quimioterapeutico para la manufactura de un medicamento para la sensibilizacion de celulas neoplasicas resistentes a agentes quimioterapeuticos con reovirus
EP1370643A1 (en) * 2001-03-16 2003-12-17 Oncolytics Biotech, Inc. Method of extracting virus from cell culture
US6942633B2 (en) * 2002-03-22 2005-09-13 Twin Star Medical, Inc. System for treating tissue swelling
ES2239928T3 (es) * 2002-05-09 2009-02-16 Oncolytics Biotech Inc. Metodo para reducir el dolor utilizando virus oncoliticos.
US20040010218A1 (en) * 2002-07-11 2004-01-15 Henderson Barbara W. Photodynamic therapy for the enhancement of vascular permeability to aid in drug delivery to diseased tissues
EP2269618A1 (en) * 2002-08-12 2011-01-05 Jennerex Biotherapeutics ULC An oncolytic vaccinia virus for use in combination with a chemotherapy for treating cancer.
US7459154B2 (en) * 2002-12-26 2008-12-02 Cell Genesys, Inc. Methods and reagents for the enhancement of virus transduction in the bladder epithelium
NZ595313A (en) * 2005-02-18 2013-03-28 Abraxis Bioscience Llc The Use Of Nanoparticles Comprising Rapamycin Or Taxane In The Treatment Of Proliferative Diseases
AU2007215328A1 (en) * 2006-02-13 2007-08-23 Oncolytics Biotech Inc. Use of local immune suppression to enhance oncolytic viral therapy
CA2678721C (en) * 2007-03-12 2018-02-13 Oncolytics Biotech Inc. Reoviruses having modified sequences
AR066649A1 (es) * 2007-05-21 2009-09-02 Oncolytics Biotech Inc Reovirus mutantes y metodos de elaboracion y uso de los mismos
MX2010003556A (es) * 2007-10-22 2010-04-21 Oncolytics Biotech Inc Regimen de tratamiento para trastornos proliferantes.

Also Published As

Publication number Publication date
ZA201008018B (en) 2012-01-25
IL208381A (en) 2014-03-31
MX2010012858A (es) 2010-12-20
AU2009253682A1 (en) 2009-12-03
CA2723580A1 (en) 2009-12-03
TW200951143A (en) 2009-12-16
IL208381A0 (en) 2010-12-30
EP2296678A4 (en) 2012-03-21
CN102695520A (zh) 2012-09-26
EP2296678A1 (en) 2011-03-23
JP2014040490A (ja) 2014-03-06
WO2009143610A1 (en) 2009-12-03
AU2009253682B2 (en) 2015-09-17
US20110086005A1 (en) 2011-04-14
JP2011520993A (ja) 2011-07-21

Similar Documents

Publication Publication Date Title
MX339014B (es) Modulacion de presion intersticial y suministro y distribucion viral oncolitica.
SG10201903119QA (en) Polypeptide vaccine
NZ705008A (en) Novel modulators and methods of use
TW201611843A (en) Methods of treatment with arginine deiminase
MX348657B (es) Microorganismos y vacunas dependientes de replicacion de aminoacidos no naturales.
HK1211832A1 (zh) 用於癌症療法的抗高血壓藥物的新穎配方及用法
NZ601325A (en) Compositions and methods for treating glioblastoma gbm
MX356525B (es) Vectores de virus asociados con adeno (aav) para uso en terapia de genes de coroideremia.
IN2015DN00895A (es)
IN2012DN02018A (es)
WO2010118063A3 (en) Pyruvate kinase m2 modulators, therapeutic compositions and related methods of use
IL207310A (en) Vaccines
MY176031A (en) Pharmaceutical combinations comprising a b-raf inhibitor, an egfr inhibitor and optionally a pi3k-alpha inhibitor
PH12014502029B1 (en) Treatment of cancer with tor kinase inhibitors
PH12014502628A1 (en) Compositions and methods related to the prevention and treatment of rabies infection
SG191060A1 (en) Robo1-fc fusion protein for use in the treatment of hepatocarcinoma
WO2011098778A8 (en) Peptides for vaccines against birch allergy
WO2011039646A3 (en) Papilloma virus -like particles for targeted gene delivery
WO2010080570A3 (en) Tumor therapy with antitumor agents in combination with sindbis virus-based vectors
MX2011012875A (es) Peptidos inmunoreguladores y metodos de uso.
MX2010009697A (es) Tratamientos anticancerigenos mejorados.
HK1148955A (en) Modulating interstitial pressure and oncolytic viral delivery and distribution
PL2585477T3 (pl) Rearanżowane cząsteczki wirusa tt do zastosowania w diagnozowaniu, profilaktyce i leczeniu raka oraz chorób autoimmunologicznych
MY190158A (en) Burkholderia pseudomallei outer membrane protein a
AR081479A1 (es) Procedimiento para reducir la frecuencia y/o la intensidad del trastorno de la pudricion apical en cultivos horticolas

Legal Events

Date Code Title Description
FG Grant or registration